연구동향 분석
박사

Impact of genetic polymorphism and CYP3A4 inhibition on the disposition of lobeglitazone

Oh, Eunsil 2018년

논문상세정보
인용/피인용
' Impact of genetic polymorphism and CYP3A4 inhibition on the disposition of lobeglitazone' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • cyp2c19
  • cyp2d6
  • cyp3a4
  • durg-drug interaction
  • lobeglitazone
  • oatp1b1
  • pharmacokinetic
  • thiazolidinedione
  • 로베글리타존
  • 약동학
  • 약물-약물 상호작용
  • 치아졸리딘디온
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
58 0

0.0%

' Impact of genetic polymorphism and CYP3A4 inhibition on the disposition of lobeglitazone' 의 참고문헌

  • Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48:689-723.
  • Zheng H, Schuetz E, Zeevi A, Zhang J, McCurry K, Webber S, et al. Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. The Journal of Clinical Pharmacology 2005;45:404-10.
  • Zhao P, Ragueneau‐Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. The Journal of Clinical Pharmacology 2009;49:351-9.
  • Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & therapeutics 2013;138:103-41.
  • Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics and Genomics 1993;3:256-63.
  • Yim CS, Jeong YS, Lee SY, Pyeon W, Ryu HM, Lee JH, et al. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for an rOATP1B2-Mediated Interaction in Hepatic Transport. Drug Metab Dispos 2017; doi:10.1124/dmd.116.074120.
  • Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Current drug metabolism 2008;9:384-93.
  • Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
  • Wang E-j, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrobial agents and chemotherapy 2002;46:160-5.
  • Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Molecular carcinogenesis 1995;13:129-34.
  • Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clinical pharmacokinetics 2000;38:111-80.
  • Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and Genomics 2007;17:93-101.
  • Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270: 414-23.
  • Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6. 1, CYP2D6. 10, and CYP2D6. 17. Drug metabolism and disposition 2007;35:1292-300.
  • Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-32.
  • Sauerberg P, Bury PS, Mogensen JP, Deussen HJ, Pettersson I, Fleckner J, et al. Large Dimeric Ligands with Favorable Pharmacokinetic Properties and Peroxisome Proliferator-Activated Receptor Agonist Activity in Vitro and in Vivo. Journal of Medicinal Chemistry 2003;46:4883-94.
  • Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, et al. Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6. 2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57). Drug Metabolism and Disposition 2008;36:2460-7.
  • Rendic S, Carlo FJD. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug metabolism reviews 1997;29:413-580.
  • PharmGKB [Internet]. Palo Alto (CA): Stanford University. Very Important PGx Gene Summary: SLCO1B1, CYP2C19 and CYP2D6. [Cited 2017 Apr 12]. Available from: https://www.pharmgkb.org/vip/PA134865839 (SLCO1B1), https://www.pharmgkb.org/vip/PA124 (CYP2C19), and https://www.pharmgkb.org/vip/PA128 (CYP2D6).
  • PharmGKB [Internet]. Palo Alto (CA): Stanford University. Gene: SLCO1B1, CYP2C19 and CYP2D6. [Cited 2017 Apr 12]. Available from: https://www.pharmgkb.org/gene/PA134865839/haplotype (SLCO1B1), https://www.pharmgkb.org/gene/PA124/haplotype (CYP2C19), and https://www.pharmgkb.org/gene/PA128/haplotype (CYP2D6).
  • Patterson SD, Jones B. Bioequivalence and statistics in clinical pharmacology: CRC Press; 2005.
  • Park S, Hyun YJ, Kim YR, Lee JH, Ryu S, Kim JM, et al. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers. Journal of Korean medical science 2017;32:729-36.
  • Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. British journal of clinical pharmacology 2004;58:397-402.
  • Oo C, Chen YC. The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug‐Drug Interaction Study. The Journal of Clinical Pharmacology 2009;49:368-9.
  • Oh ES, Kim CO, Kim KH, Kim YN, Kim C, Lee JI, et al. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. Clinical therapeutics 2014;36:1064-71.
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007;356:2457-71.
  • Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73:554-65.
  • Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for Inverse Effects of OATP‐C (SLC21A6)* 5 and* 1b Haplotypes on Pravastatin Kinetics. Clinical Pharmacology & Therapeutics 2004;75:415-21.
  • Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification, characterization, and tissue distribution of human peroxisome proliferatoractivated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. Journal of Biological Chemistry 1997;272:8071-6.
  • Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochemical pharmacology 2003;65:1843-52.
  • Mikkaichi T, Nakai D, Yoshigae Y, Imaoka T, Okudaira N, Izumi T. Liverselective distribution in rats supports the importance of active uptake into the liver via organic anion transporting polypeptides (OATPs) in humans. Drug Metabolism and Pharmacokinetics 2015;30:334-40.
  • Martin G, Schoonjans K, Staels B, Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998;137 Suppl:S75-80.
  • Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 2009;45:784-8.
  • Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical Pharmacology & Therapeutics 2006;79:427-39.
  • Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort study. Diabetes care 2011;34:916-22.
  • Lee S-J, Lee SS, Jung H-J, Kim H-S, Park S-J, Yeo C-W, et al. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug metabolism and disposition 2009;37:1464-70.
  • Lee JH, Noh CK, Yim CS, Jeong YS, Ahn SH, Lee W, et al. Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. J Pharm Sci. 2015; 104: 3049-59.
  • Lee HW, Bok YK, Joong BA, Sung KK, Lee JH, Jae SS, et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. European Journal of Medicinal Chemistry 2005;40:862-74.
  • Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein. Clinical Pharmacology & Therapeutics 2002;72:209-19.
  • Kim S-M, Ha N, Park K-T, Oh H-T, Yu H, Kim YM, et al. Absorption, Distribution, Metabolism and Excretion (ADME) Study With a Potent Thiazolidinedione Insulin Sensitizer, Lobeglitazone. The 9th International ISSX meeting; 2010 Sep; Istanbul, Turkey. Taylor & Francis Inc; 2010.
  • Kim JW, Kim J-R, Yi S, Shin K-H, Shin H-S, Yoon SH, et al. Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects. Clinical Therapeutics 2011;33:1819-30.
  • Kim HS, Cho DY, Park BM, Bae SK, Yoon YJ, Oh M, et al. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. The Journal of Clinical Pharmacology 2014;54:850-7.
  • Kim E-Y, Cho D-Y, Shin H-J, Lee S-S, Shon J-H, Shin J-G, et al. Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations. Clinica Chimica Acta 2008;388:68-72.
  • Kim BY, Ahn JB, Lee HW, Moon KS, Sim TB, Shin JS, et al. Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives. Chemical and Pharmaceutical Bulletin 2003;51:276-85.
  • Kim BY, Ahn JB, Lee HW, Kang SK, Lee JH, Shin JS, et al. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. European Journal of Medicinal Chemistry 2004;39:433-47.
  • Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1* 1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics and genomics 2008;18:937-42.
  • Johne A, K pke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene. Clinical Pharmacology & Therapeutics 2002;72:584-94.
  • Jin S, Chung H, Chung M, Kim JI, Kang JH, Woo S, et al. Influence of CYP2D6* 10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. Journal of clinical pharmacy and therapeutics 2008;33:567-73.
  • Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clinical Pharmacology & Therapeutics 2005;77:404-14.
  • Ibrahim IA, Kang E, Dansky KH. Polypharmacy and Possible Drug-Drug Interactions Among Diabetic Patients Receiving Home Health Care Services. Home Health Care Services Quarterly 2005;24:87-99.
  • Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992;15:1075-9.
  • Ho WF, Koo SH, Yee JY, Lee EJ. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet 2008;23:476-82.
  • Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics and Genomics 2004;14:147-54.
  • Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, et al. Molecular and physical mechanisms of first-pass extraction. Drug metabolism and disposition 1999;27:161-6.
  • Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta (BBA)-Biomembranes 2003;1609:1-18.
  • Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, et al. Insulin sensitivity and acute insulin response in African-Americans, non- Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 1997;46:63-9.
  • Guidance for Industry. Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (2012). US FDA.
  • Guidance for Industry. Clinical Drug Interaction Studies — Study Design, Data Analysis, and Clinical Implications (2017). US FDA.
  • Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectrum 2002;15:240-8.
  • Ferr P. The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 2004;53:S43-S50.
  • FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects. US FDA. [Cited 2017 Nov 7]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm371017.htm.
  • Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 1984;25:1-3.
  • CKD-501 invesitagor's brochure, version 10. Chong Kun Dang Pharmaceutical Corp. Korea.
  • Bertino JS. Pharmacogenomics - An Introduction and Clinical Perspective: McGraw Hill Professional; 2013.
  • Avandia rosiglitazone maleate [package insert]. GlaxoSmithKline. [Cited 2017 Jan 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21071lbl.pdf.
  • Alberti KGMM, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine 1998;15:539-53.
  • Actos pioglitazone hydrochloride [package insert]. Takeda Pharmaceuticals. [Cited 2017 Jan 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21073lbl.pdf.